Vivos Therapeutics (NASDAQ:VVOS – Get Rating) had its target price decreased by Craig Hallum to $5.00 in a research report issued to clients and investors on Tuesday, Stock Target Advisor reports. The firm presently has a “na” rating on the stock. Craig Hallum’s target price points to a potential upside of 262.32% from the company’s previous close.
Separately, Zacks Investment Research cut Vivos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 9th.
NASDAQ VVOS traded up $0.03 during trading hours on Tuesday, hitting $1.38. 1 shares of the company were exchanged, compared to its average volume of 76,123. The stock has a 50-day moving average price of $2.13 and a 200 day moving average price of $2.54. Vivos Therapeutics has a 52 week low of $1.18 and a 52 week high of $7.09. The stock has a market cap of $31.75 million, a PE ratio of -1.41 and a beta of 0.84.
About Vivos Therapeutics (Get Rating)
Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
- Get a free copy of the StockNews.com research report on Vivos Therapeutics (VVOS)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
- Beware The Rebound In Home Depot
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.